News
Q2 2025 Revenue Guidance: $95 million to $120 million. Emergent BioSolutions Inc (NYSE:EBS) delivered on their revenue and adjusted EBITDA targets for Q1 2025, improving their cash and liquidity ...
Including – as was widely reported over the weekend – checkmate his opponents on the chessboard. Prior to the Eagles’ match against Forest, the 26-year-old England international was centre stage at ...
Leading bank AIB is cutting some of its mortgage rates and also reducing two deposit interest rates. The moves comes after the European Central Bank announced its seventh cut in its rates earlier ...
Auto aficionados should have plenty to enjoy this weekend as Jamaica Auto Show (JAS) 2025 opens at 10:00 am on Saturday, May 10, and runs through Sund ...
Keith Kellogg, President Trump’s special envoy to Ukraine, condemned Russia’s attack on a Palm Sunday gathering in Ukraine. “Today’s Palm Sunday attack by Russian forces on civilian ...
While attending Notre Dame College -- where she was part of the last graduating class in spring 2024 -- Klein was a member of the college’s bowling team. Fire Chief David Csire noted that Klein ...
Shortly after taking office, the Trump Administration announced the suspension of refugee resettlement, a program that offers safety to some of the most vulnerable refugees in the world and has saved ...
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement
Emergent BioSolutions EBS secured over $1 billion in government and pharmaceutical contracts during the COVID-19 pandemic. However, in March 2021, workers at its Baltimore facility mistakenly ...
EBS-C will consolidate several Army business systems onto a single SAP-powered platform. In its complaint, Groundswell says that the Army changed the parameters of the evaluation in the middle of ...
The U.S. Army is rolling out its latest and greatest business system modernization program: the Enterprise Business Systems – Convergence (EBS-C). Think of it as a corporate makeover show ...
The psychological thriller, based on the trilogy of novels by Swedish crime-writing duo Jerker Eriksson and Hakan Axlander Sundquist, who write under the pseudonym Erik Axl Sund, is currently in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results